Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
$0.79
-21.7%
$6.76
$2.06
$7.01
$110.80M1.598.44 million shs1,910 shs
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$4.34
+2.6%
$5.89
$1.18
$9.39
$495.80M1.811.90 million shs58,927 shs
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$17.86
+1.4%
$19.32
$10.65
$22.09
$1.26B0.27399,844 shs54,273 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$38.12
-0.1%
$41.82
$15.50
$52.57
$2.29B1.9618,244 shs53,261 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
0.00%0.00%0.00%0.00%+259.63%
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-1.86%-10.76%-36.58%+45.36%+178.29%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-1.40%+4.32%-11.82%-3.35%+57.94%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-3.93%+0.10%-3.49%-13.98%+81.24%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
4.6538 of 5 stars
4.54.00.04.70.03.30.6
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
1.8363 of 5 stars
3.51.00.00.02.43.30.0
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.6158 of 5 stars
2.50.00.04.32.50.80.6
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
3.00
Buy$11.00153.46% Upside
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
3.00
Buy$30.0067.97% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.00
Buy$47.2023.82% Upside
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A

Current Analyst Ratings

Latest ZIOP, APLT, KNSA, RYTM, and ACHN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/24/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$25.00 ➝ $30.00
4/23/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
4/18/2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$53.00 ➝ $52.00
4/11/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$12.00
4/10/2024
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
4/2/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$28.00 ➝ $30.00
3/26/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
3/15/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $13.00
3/6/2024
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $12.00
2/28/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$28.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/A$1.92 per shareN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
$9.99M49.63N/AN/A($0.20) per share-21.70
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$270.26M4.67N/AN/A$6.23 per share2.87
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$77.43M29.61N/AN/A$2.87 per share13.28
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
-$70.27M-$0.51N/AN/AN/AN/A-30.95%-29.09%N/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$119.76M-$1.35N/AN/AN/AN/AN/A-275.83%5/9/2024 (Estimated)
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$14.08M$0.11162.38N/A2.78%-7.32%-6.15%7/23/2024 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$184.68M-$3.20N/AN/AN/A-238.50%-96.02%-55.02%5/7/2024 (Confirmed)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest ZIOP, APLT, KNSA, RYTM, and ACHN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$2.12N/A+$2.12N/AN/AN/A  
4/23/2024Q1 2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.14-$0.25-$0.11-$0.25$76.97 million$79.90 million    
3/6/2024Q4 2023
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
-$0.15-$0.33-$0.18-$0.33N/A($0.67) million
2/28/2024Q4 2023
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.11$0.04+$0.15-$0.27$72.31 million$83.40 million
2/22/2024Q4 2023
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.70-$0.70N/A-$0.70$25.38 million$24.23 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/AN/A
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
0.01
8.96
8.96
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
N/A
0.76
0.76
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/A
4.34
3.85
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
5.58
5.43
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
56140.05 millionN/AOptionable
Applied Therapeutics, Inc. stock logo
APLT
Applied Therapeutics
25114.24 million92.42 millionOptionable
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
29770.61 million32.32 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
22660.14 million57.31 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

ZIOP, APLT, KNSA, RYTM, and ACHN Headlines

SourceHeadline
Childhood CancersChildhood Cancers
curetoday.com - February 17 at 5:57 PM
Alx Oncology Holdings (ALXO)Alx Oncology Holdings (ALXO)
investing.com - February 10 at 8:15 PM
Pediatric Hematology-Oncology FellowshipPediatric Hematology-Oncology Fellowship
bcm.edu - February 5 at 8:39 AM
Alaunos Therapeutics: Other Events, Financial Statements And ExhibitsAlaunos Therapeutics: Other Events, Financial Statements And Exhibits
cbonds.com - January 31 at 9:44 AM
CG Oncology IncCG Oncology Inc
reuters.com - January 31 at 4:43 AM
Oncology Nurses Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients
medscape.com - December 21 at 3:43 PM
Immuno-OncologyImmuno-Oncology
ajmc.com - December 19 at 3:21 PM
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
markets.businessinsider.com - December 18 at 8:18 AM
Exploring Patient-Centered Handoffs in Surgical OncologyExploring Patient-Centered Handoffs in Surgical Oncology
medscape.com - December 10 at 7:36 PM
Association of Community Cancer CentersAssociation of Community Cancer Centers
ajmc.com - October 14 at 2:50 PM
Oncology News and ResearchOncology News and Research
news-medical.net - September 19 at 5:53 PM
WBSPH 2024 - OncologyWBSPH 2024 - Oncology
newsweek.com - September 15 at 8:49 PM
Kris on OncologyKris on Oncology
medscape.com - September 6 at 11:16 PM
Gauging Ziopharms Chances for Positive Sarcoma Drug Trial ResultsGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
thestreet.com - August 29 at 6:23 AM
Oncology Cases & QuizzesOncology Cases & Quizzes
medscape.com - August 14 at 6:15 PM
Ziopharm’s palifosfamide fails in first-line STS…Ziopharm’s palifosfamide fails in first-line STS…
investing.com - June 21 at 12:05 AM
Weber on OncologyWeber on Oncology
medscape.com - June 19 at 2:11 PM
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
ascopubs.org - June 17 at 8:43 AM
ALX Oncology Holdings Inc Ordinary SharesALX Oncology Holdings Inc Ordinary Shares
morningstar.com - June 15 at 6:54 PM
Division of Pediatric Hematology and OncologyDivision of Pediatric Hematology and Oncology
slu.edu - June 13 at 3:50 PM
Division of Hematology and Medical OncologyDivision of Hematology and Medical Oncology
slu.edu - June 13 at 3:50 PM
Intratumoral Cancer Therapies Global Market Report 2023Intratumoral Cancer Therapies Global Market Report 2023
finance.yahoo.com - June 9 at 1:32 PM
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
marketwatch.com - May 11 at 9:52 PM
VC Identifies 3 Startups That Will Shake Up the Future of Cancer CareVC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Achillion Pharmaceuticals logo

Achillion Pharmaceuticals

NASDAQ:ACHN
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Applied Therapeutics logo

Applied Therapeutics

NASDAQ:APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

NASDAQ:KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Rhythm Pharmaceuticals logo

Rhythm Pharmaceuticals

NASDAQ:RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
ZIOPHARM Oncology logo

ZIOPHARM Oncology

NASDAQ:ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.